Evidence map›Paper›PMID 34526696›Full record

ReviewNature reviews. Drug discovery2022

Advances in TRP channel drug discovery: from target validation to clinical studies.

Ari-Pekka Koivisto, Maria G Belvisi, Rachelle Gaudet, Arpad Szallasi

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 4 pooled it
45.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 4 syntheses or guidelines pooled it, 513 citations in OpenAlex.

  1. Pooled it
  2. [Research progress on the causes of pain in knee osteoarthritis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. TRPV4 mediates low-humidity responses in epidermal keratinocytes.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  12. Article
  13. Symmetry-driven gating of TRPM8 by PIPNature communications · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. The role of IPPflugers Archiv : European journal of physiology · 2026
    Review
  20. Article

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 5 countries.

Ari-Pekka KoivistoR&D, Neurological Disorders Research, Orion Pharma, Turku, Finland.ORCID 0000-0003-1389-9521
Maria G BelvisiResearch & Early Development, Respiratory & Immunology BioPharmaceuticals-R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-1652-4370
Rachelle GaudetDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0002-9177-054X
Arpad Szallasi1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. szallasiarpad@gmail.com.ORCID 0000-0001-7236-5373
AstraZeneca (Sweden) · SEHarvard University · USOrion Corporation (Finland) · FISemmelweis University · HU

Funding

Towards molecular mechanisms of invertebrate Gustatory ReceptorsR21DC018497 · NIDCD · BRANDEIS UNIVERSITY · PI GARRITY, PAUL, GAUDET, RACHELLE · 2020 to 2021
$453k
NIDCD NIH HHS R21 DC018497
6 · The paper itself

Abstract

Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels.

Indexed as

AnimalsDrug Delivery SystemsDrug DiscoveryHumansTransient Receptor Potential ChannelsTransient Receptor Potential Channels

Identifiers

PMID34526696
PMCPMC8442523
OpenAlexW3199382522

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.